Immuron Says Monthly Sales Of Its OTC Gastrointestinal And Digestive Health Immune Supplement Travelan Increased By 7984% In August 2023 To A$1.18M Compared To A$14,581 A Year Ago
Portfolio Pulse from Benzinga Newsdesk
Immuron reported a 7984% increase in monthly sales of its over-the-counter gastrointestinal and digestive health immune supplement, Travelan, in August 2023, reaching A$1.18M compared to A$14,581 a year ago. This follows the resolution of short term stock outages of Travelan in some wholesalers and pharmacies in the June 2023 quarter.
September 13, 2023 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immuron's significant increase in sales of Travelan could positively impact its stock price in the short term.
The reported 7984% increase in sales of Travelan indicates a strong demand for the product, which could lead to increased revenues for Immuron. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100